Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
Profitability ratio | Description | The company |
---|---|---|
Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Zoetis Inc. gross profit margin ratio improved from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Zoetis Inc. operating profit margin ratio improved from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Zoetis Inc. net profit margin ratio improved from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Zoetis Inc. ROE improved from Q3 2021 to Q4 2021 but then slightly deteriorated from Q4 2021 to Q1 2022. |
ROA | A profitability ratio calculated as net income divided by total assets. | Zoetis Inc. ROA improved from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
Gross Profit Margin
Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Gross profit | 1,417) | 1,367) | 1,404) | 1,380) | 1,322) | 1,206) | 1,240) | 1,097) | 1,075) | 1,144) | 1,105) | 1,082) | 937) | 1,020) | 1,007) | 968) | 919) | 1,003) | 912) | 829) | 788) | |||||||
Revenue | 1,986) | 1,967) | 1,990) | 1,948) | 1,871) | 1,807) | 1,786) | 1,548) | 1,534) | 1,674) | 1,584) | 1,547) | 1,455) | 1,564) | 1,480) | 1,415) | 1,366) | 1,460) | 1,347) | 1,269) | 1,231) | |||||||
Profitability Ratio | ||||||||||||||||||||||||||||
Gross profit margin1 | 70.56% | 70.38% | 69.75% | 69.45% | 69.38% | 69.18% | 69.64% | 69.73% | 69.51% | 68.18% | 67.38% | 66.92% | 66.49% | 67.19% | 68.12% | 68.04% | 67.31% | 66.55% | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||
Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | 69.53% | 68.96% | 67.72% | 65.62% | 64.82% | 66.41% | 68.74% | 73.56% | 77.43% | 77.64% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Amgen Inc. | 73.30% | 73.44% | 74.00% | 73.97% | 74.37% | 74.59% | 75.55% | 77.15% | 78.90% | 80.38% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Bristol-Myers Squibb Co. | 79.62% | 78.57% | 76.92% | 75.88% | 74.42% | 72.31% | 71.18% | 69.47% | 68.02% | 69.10% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Eli Lilly & Co. | 74.40% | 74.18% | 74.85% | 74.27% | 75.88% | 77.66% | 78.26% | 78.67% | 79.22% | 78.85% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Gilead Sciences Inc. | 75.50% | 75.56% | 80.23% | 79.90% | 80.32% | 81.23% | 78.72% | 78.25% | 79.06% | 78.86% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Johnson & Johnson | 67.97% | 68.16% | 67.51% | 67.00% | 66.24% | 65.58% | 65.68% | 65.66% | 66.15% | 66.42% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Merck & Co. Inc. | 70.72% | 72.02% | 67.95% | 67.48% | 66.99% | 67.74% | 71.23% | 70.06% | 70.11% | 69.87% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Pfizer Inc. | 60.35% | 62.08% | 65.28% | 70.96% | 76.46% | 79.26% | 80.47% | 80.19% | 80.03% | 80.25% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | 84.65% | 84.83% | 86.65% | 86.85% | 86.84% | 86.82% | 87.98% | 88.21% | 89.72% | 90.05% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Thermo Fisher Scientific Inc. | 48.37% | 50.08% | 51.05% | 51.29% | 51.47% | 49.67% | 47.31% | 45.39% | 44.30% | 44.35% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Vertex Pharmaceuticals Inc. | 87.95% | 88.06% | 87.94% | 87.89% | 88.06% | 88.14% | 88.01% | 87.71% | 87.24% | 86.84% | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Q1 2022 Calculation
Gross profit margin = 100
× (Gross profitQ1 2022
+ Gross profitQ4 2021
+ Gross profitQ3 2021
+ Gross profitQ2 2021)
÷ (RevenueQ1 2022
+ RevenueQ4 2021
+ RevenueQ3 2021
+ RevenueQ2 2021)
= 100 × (1,417 + 1,367 + 1,404 + 1,380)
÷ (1,986 + 1,967 + 1,990 + 1,948)
= 70.56%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Zoetis Inc. gross profit margin ratio improved from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
Operating Profit Margin
Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Operating income | 787) | 592) | 719) | 703) | 746) | 510) | 659) | 545) | 530) | 482) | 558) | 504) | 423) | 422) | 453) | 479) | 459) | 497) | 457) | 384) | 368) | |||||||
Revenue | 1,986) | 1,967) | 1,990) | 1,948) | 1,871) | 1,807) | 1,786) | 1,548) | 1,534) | 1,674) | 1,584) | 1,547) | 1,455) | 1,564) | 1,480) | 1,415) | 1,366) | 1,460) | 1,347) | 1,269) | 1,231) | |||||||
Profitability Ratio | ||||||||||||||||||||||||||||
Operating profit margin1 | 35.50% | 35.49% | 35.16% | 35.32% | 35.08% | 33.62% | 33.87% | 33.36% | 32.72% | 31.42% | 31.01% | 29.80% | 30.05% | 31.12% | 33.00% | 33.86% | 33.02% | 32.15% | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||
Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | 32.68% | 31.89% | 30.09% | 28.95% | 23.63% | 24.81% | 28.45% | 30.17% | 39.86% | 39.03% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Amgen Inc. | 32.78% | 31.44% | 30.14% | 30.72% | 37.23% | 37.70% | 38.59% | 39.76% | 41.89% | 43.57% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Bristol-Myers Squibb Co. | 16.79% | 15.91% | -15.73% | -17.02% | -19.19% | -21.60% | 9.27% | 11.67% | 16.30% | 22.62% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Eli Lilly & Co. | 25.94% | 22.45% | 23.17% | 21.81% | 22.06% | 24.69% | 23.55% | 24.48% | 25.64% | 22.29% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Gilead Sciences Inc. | 26.56% | 36.72% | 42.79% | 37.20% | 18.07% | 16.72% | 11.01% | -4.40% | 19.89% | 19.38% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Johnson & Johnson | 23.76% | 24.95% | 24.69% | 25.23% | 24.10% | 23.60% | 24.30% | 24.64% | 25.62% | 24.15% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Merck & Co. Inc. | 28.85% | 25.74% | 14.07% | 10.64% | 14.02% | 16.47% | 26.87% | 25.40% | 25.49% | 24.77% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Pfizer Inc. | 26.12% | 23.91% | 24.67% | 24.12% | 21.20% | 19.47% | 21.17% | 21.17% | 24.20% | 25.46% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | 55.08% | 55.67% | 55.19% | 53.94% | 43.37% | 42.09% | 37.43% | 34.64% | 30.45% | 28.10% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Thermo Fisher Scientific Inc. | 23.83% | 25.57% | 27.04% | 28.00% | 27.68% | 24.19% | 20.90% | 17.05% | 17.86% | 17.99% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Vertex Pharmaceuticals Inc. | 36.93% | 36.73% | 37.17% | 33.93% | 47.14% | 46.03% | 44.43% | 38.67% | 34.05% | 28.77% | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Q1 2022 Calculation
Operating profit margin = 100
× (Operating incomeQ1 2022
+ Operating incomeQ4 2021
+ Operating incomeQ3 2021
+ Operating incomeQ2 2021)
÷ (RevenueQ1 2022
+ RevenueQ4 2021
+ RevenueQ3 2021
+ RevenueQ2 2021)
= 100 × (787 + 592 + 719 + 703)
÷ (1,986 + 1,967 + 1,990 + 1,948)
= 35.50%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Zoetis Inc. operating profit margin ratio improved from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
Net Profit Margin
Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Net income attributable to Zoetis Inc. | 595) | 414) | 552) | 512) | 559) | 359) | 479) | 377) | 423) | 384) | 433) | 371) | 312) | 345) | 347) | 384) | 352) | 81) | 298) | 247) | 238) | |||||||
Revenue | 1,986) | 1,967) | 1,990) | 1,948) | 1,871) | 1,807) | 1,786) | 1,548) | 1,534) | 1,674) | 1,584) | 1,547) | 1,455) | 1,564) | 1,480) | 1,415) | 1,366) | 1,460) | 1,347) | 1,269) | 1,231) | |||||||
Profitability Ratio | ||||||||||||||||||||||||||||
Net profit margin1 | 26.27% | 26.20% | 26.02% | 25.76% | 25.30% | 24.54% | 25.42% | 25.50% | 25.41% | 23.96% | 23.76% | 22.74% | 23.47% | 24.52% | 20.35% | 19.95% | 17.97% | 16.28% | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||
Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | 22.00% | 20.54% | 13.66% | 12.40% | 10.28% | 10.08% | 18.16% | 19.20% | 24.77% | 23.69% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Amgen Inc. | 23.42% | 24.25% | 23.03% | 23.80% | 29.60% | 29.97% | 30.91% | 31.53% | 33.64% | 35.32% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Bristol-Myers Squibb Co. | 13.31% | 15.08% | -11.89% | -11.44% | -14.53% | -21.20% | -0.11% | -1.61% | 3.08% | 13.15% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Eli Lilly & Co. | 20.90% | 19.71% | 21.52% | 22.71% | 23.91% | 25.24% | 24.01% | 24.48% | 23.97% | 37.27% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Gilead Sciences Inc. | 16.60% | 23.05% | 27.21% | 19.62% | 1.19% | 0.51% | 5.56% | -1.18% | 22.17% | 24.35% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Johnson & Johnson | 20.90% | 22.26% | 19.55% | 19.92% | 17.95% | 17.82% | 21.01% | 18.86% | 20.75% | 18.42% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Merck & Co. Inc. | 26.27% | 26.79% | 15.09% | 11.83% | 15.09% | 14.72% | 24.33% | 22.20% | 21.10% | 21.01% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Pfizer Inc. | 27.01% | 27.04% | 28.77% | 23.86% | 24.03% | 22.95% | 18.59% | 31.31% | 32.32% | 31.45% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | 48.06% | 50.25% | 51.65% | 50.11% | 43.53% | 41.35% | 38.28% | 37.30% | 28.56% | 26.91% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Thermo Fisher Scientific Inc. | 18.49% | 19.70% | 21.93% | 22.47% | 22.08% | 19.79% | 17.12% | 14.12% | 14.31% | 14.47% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Vertex Pharmaceuticals Inc. | 30.84% | 30.92% | 30.52% | 29.80% | 43.06% | 43.70% | 44.91% | 38.51% | 31.35% | 28.27% | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Q1 2022 Calculation
Net profit margin = 100
× (Net income attributable to Zoetis Inc.Q1 2022
+ Net income attributable to Zoetis Inc.Q4 2021
+ Net income attributable to Zoetis Inc.Q3 2021
+ Net income attributable to Zoetis Inc.Q2 2021)
÷ (RevenueQ1 2022
+ RevenueQ4 2021
+ RevenueQ3 2021
+ RevenueQ2 2021)
= 100 × (595 + 414 + 552 + 512)
÷ (1,986 + 1,967 + 1,990 + 1,948)
= 26.27%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Zoetis Inc. net profit margin ratio improved from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
Return on Equity (ROE)
Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Net income attributable to Zoetis Inc. | 595) | 414) | 552) | 512) | 559) | 359) | 479) | 377) | 423) | 384) | 433) | 371) | 312) | 345) | 347) | 384) | 352) | 81) | 298) | 247) | 238) | |||||||
Total Zoetis Inc. equity | 4,658) | 4,543) | 4,679) | 4,350) | 4,089) | 3,769) | 3,602) | 2,982) | 2,753) | 2,708) | 2,678) | 2,411) | 2,317) | 2,185) | 2,118) | 1,970) | 1,960) | 1,770) | 1,989) | 1,715) | 1,609) | |||||||
Profitability Ratio | ||||||||||||||||||||||||||||
ROE1 | 44.50% | 44.84% | 42.36% | 43.89% | 43.38% | 43.46% | 46.17% | 54.23% | 58.52% | 55.39% | 54.56% | 57.03% | 59.91% | 65.35% | 54.96% | 56.60% | 49.90% | 48.81% | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||
ROE, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | 76.64% | 74.91% | 55.60% | 53.01% | 37.63% | 35.30% | 48.34% | 47.30% | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Amgen Inc. | 624.78% | 87.96% | 68.26% | 69.67% | 75.91% | 77.20% | 67.09% | 68.48% | 80.92% | 81.07% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Bristol-Myers Squibb Co. | 19.79% | 19.46% | -14.52% | -13.80% | -16.54% | -23.84% | -0.09% | -1.15% | 1.91% | 6.66% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Eli Lilly & Co. | 65.69% | 62.16% | 76.99% | 94.20% | 88.31% | 109.79% | 115.45% | 137.26% | 179.72% | 319.09% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Gilead Sciences Inc. | 22.66% | 29.55% | 34.44% | 26.20% | 1.59% | 0.68% | 7.27% | -1.43% | 22.49% | 23.91% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Johnson & Johnson | 26.54% | 28.20% | 25.44% | 25.53% | 22.96% | 23.25% | 26.35% | 24.11% | 28.01% | 25.42% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Merck & Co. Inc. | 34.68% | 34.17% | 20.10% | 16.73% | 26.08% | 27.91% | 39.47% | 37.91% | 38.72% | 37.99% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Pfizer Inc. | 30.29% | 28.47% | 26.28% | 18.86% | 16.23% | 15.21% | 12.22% | 22.05% | 24.21% | 25.77% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | 39.84% | 43.03% | 40.53% | 41.02% | 33.43% | 31.86% | 31.17% | 32.94% | 18.79% | 19.08% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Thermo Fisher Scientific Inc. | 18.56% | 18.94% | 22.13% | 23.32% | 22.60% | 18.47% | 15.33% | 12.41% | 12.85% | 12.45% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Vertex Pharmaceuticals Inc. | 22.47% | 23.19% | 22.83% | 21.66% | 30.76% | 31.22% | 33.08% | 27.67% | 23.38% | 19.34% | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Q1 2022 Calculation
ROE = 100
× (Net income attributable to Zoetis Inc.Q1 2022
+ Net income attributable to Zoetis Inc.Q4 2021
+ Net income attributable to Zoetis Inc.Q3 2021
+ Net income attributable to Zoetis Inc.Q2 2021)
÷ Total Zoetis Inc. equity
= 100 × (595 + 414 + 552 + 512)
÷ 4,658 = 44.50%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Zoetis Inc. ROE improved from Q3 2021 to Q4 2021 but then slightly deteriorated from Q4 2021 to Q1 2022. |
Return on Assets (ROA)
Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Net income attributable to Zoetis Inc. | 595) | 414) | 552) | 512) | 559) | 359) | 479) | 377) | 423) | 384) | 433) | 371) | 312) | 345) | 347) | 384) | 352) | 81) | 298) | 247) | 238) | |||||||
Total assets | 13,860) | 13,900) | 13,705) | 14,069) | 13,796) | 13,609) | 13,725) | 13,069) | 11,528) | 11,545) | 11,272) | 10,986) | 10,883) | 10,777) | 10,459) | 8,603) | 8,690) | 8,586) | 9,288) | 7,802) | 7,649) | |||||||
Profitability Ratio | ||||||||||||||||||||||||||||
ROA1 | 14.96% | 14.65% | 14.46% | 13.57% | 12.86% | 12.04% | 12.12% | 12.37% | 13.97% | 12.99% | 12.96% | 12.52% | 12.75% | 13.25% | 11.13% | 12.96% | 11.25% | 10.06% | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||
ROA, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | 8.71% | 7.88% | 5.06% | 4.50% | 3.43% | 3.07% | 4.93% | 4.65% | 9.25% | 8.84% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Amgen Inc. | 9.67% | 9.63% | 8.63% | 9.61% | 11.33% | 11.54% | 11.37% | 11.23% | 12.45% | 13.13% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Bristol-Myers Squibb Co. | 6.07% | 6.40% | -4.87% | -4.58% | -5.53% | -7.61% | -0.04% | -0.44% | 0.74% | 2.65% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Eli Lilly & Co. | 13.06% | 11.44% | 12.39% | 12.70% | 13.01% | 13.28% | 12.68% | 13.39% | 13.46% | 21.17% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Gilead Sciences Inc. | 7.16% | 9.16% | 11.02% | 7.59% | 0.45% | 0.18% | 2.08% | -0.46% | 8.31% | 8.74% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Johnson & Johnson | 11.12% | 11.47% | 9.98% | 10.07% | 8.76% | 8.41% | 9.95% | 9.59% | 11.07% | 9.59% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Merck & Co. Inc. | 13.29% | 12.35% | 7.70% | 6.14% | 7.73% | 7.72% | 12.83% | 11.56% | 11.95% | 11.66% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Pfizer Inc. | 13.58% | 12.11% | 11.10% | 7.78% | 7.01% | 6.23% | 4.46% | 7.97% | 9.47% | 9.72% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | 30.11% | 31.75% | 29.55% | 28.88% | 22.53% | 20.47% | 19.62% | 20.68% | 14.46% | 14.29% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Thermo Fisher Scientific Inc. | 8.20% | 8.12% | 11.64% | 12.70% | 12.02% | 9.23% | 7.62% | 6.02% | 6.25% | 6.33% | — | — | — | — | — | — | — | — | — | — | — | |||||||
Vertex Pharmaceuticals Inc. | 17.19% | 17.44% | 17.25% | 16.30% | 22.80% | 23.07% | 23.81% | 20.37% | 16.99% | 14.15% | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Q1 2022 Calculation
ROA = 100
× (Net income attributable to Zoetis Inc.Q1 2022
+ Net income attributable to Zoetis Inc.Q4 2021
+ Net income attributable to Zoetis Inc.Q3 2021
+ Net income attributable to Zoetis Inc.Q2 2021)
÷ Total assets
= 100 × (595 + 414 + 552 + 512)
÷ 13,860 = 14.96%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROA | A profitability ratio calculated as net income divided by total assets. | Zoetis Inc. ROA improved from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |